Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pulmoe.2022.04.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Osimertinib-induced lymphocytopenia and pneumocystis jirovecii pneumonia.
Pulmonology
September 2022
Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan. Electronic address:
Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis.
Am J Case Rep
September 2021
Department of Internal Medicine, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Chiba, Japan.
BACKGROUND Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced non-small cell lung cancer (NSCLC) with positive EGFR mutation. Rashes, nail toxicity, and diarrhea are common adverse events. Hematological adverse effects, including anemia, thrombocytopenia, and lymphocytopenia, have been reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!